Enveda closed a $311 million Series E round as it advances compounds into human trials.
Why it matters: The deal shows investors are still willing to fund biotech platforms that can produce clinical data, even as the sector faces a tougher financing environment. For executives and investors, the key question is whether Enveda can turn discovery claims into repeatable trial results and a commercial pipeline.
- Enveda said Sept. 23, 2026, that it closed a $311 million Series E round.
- TechCrunch reported the round valued the Boulder-area biotech at $2 billion.
- Catalio Capital Management led the financing, with participation from ICONIQ and other investors.
- The company says the capital will support its clinical pipeline and additional compounds moving into human testing.
Enveda raised $311 million as it tries to turn AI-discovered, nature-derived compounds into clinical-stage medicines. The company said the new capital will support its clinical pipeline and help advance more compounds into human testing, according to TechCrunch and its announcement.
TechCrunch reported the financing was led by Catalio Capital Management, with participation from ICONIQ and other investors. The outlet also said the round valued Enveda at $2 billion.
Enveda was founded in 2019 by Viswa Colluru, an early employee of Recursion Pharmaceuticals. The company's approach is to identify medicines in plants and microbes, then use AI tools to help develop them.
On its pipeline page, Enveda lists three named assets: ENV-294 for atopic dermatitis and asthma, ENV-308 for post-weight-loss maintenance, and ENV-6946 for inflammatory bowel disease. The company says ENV-294 has completed Phase 1b and started Phase 2a, while ENV-308 and ENV-6946 are both in Phase 1. Enveda's pipeline page includes those stage details.
Enveda also has posted updates on its own site about ENV-308 and ENV-294, including Phase 1 tolerability and exploratory biomarker findings for ENV-308 and Phase 1b results for ENV-294. Those details are company-reported and should be read alongside the company's broader pipeline disclosures.
Fierce Biotech reported that Enveda previously raised $130 million in Series C funding in November 2024 and $150 million in Series D funding in September 2025.
By the numbers
- $311 million - size of Enveda's Series E round, announced Sept. 23, 2026.
- $2 billion - valuation TechCrunch reported for the company.
- 3 - named pipeline assets listed on Enveda's site.
Yes, but: Several of Enveda's clinical milestone details come from company disclosures, not independent trial reporting, so the progress should be treated as company-reported until corroborated.
What's next: Enveda says ENV-308 is headed toward a Phase 2 trial, while ENV-294 and ENV-6946 remain in earlier-stage development.